Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 9/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.40 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451893 | 1.00 | ADAM17 (0.52) | ADAM17HTR2CATML3MBTL1NTRK3 | |
| SCHEMBL2823324 | 0.86 | ATM (0.56) | ADAM17ATML3MBTL1 | |
| SCHEMBL11075435 | 0.83 | ADAM17 (0.49) | ADAM17ATML3MBTL1 | |
| SCHEMBL11078762 | 0.82 | ADAM17 (0.47) | ADAM17HTT | |
| SCHEMBL11470653 | 0.82 | ADAM17 (0.42) | ADAM17 | |
| SCHEMBL3984092 | 0.79 | ADAM17 (0.53) | ADAM17 | |
| SCHEMBL4776144 | 0.78 | HTR2C (0.57) | HTR2C | |
| SCHEMBL11082553 | 0.78 | ADAM17 (0.45) | ADAM17 | |
| SCHEMBL15607721 | 0.77 | HTR2C (0.56) | HTR2C | |
| SCHEMBL19860381 | 0.77 | HTR2C (0.56) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009538-A1 | Methods and compositions for the treatment of urinary incontinence | DOV PHARMACEUTICAL, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070149599-A1 | Polymorphs of bicifadine hydrochloride | DOV PHARMACEUTICAL, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070082938-A1 | Polymorphs of bicifadine hydrochloride | DOV PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| WO-2007014264-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIES AND RELATED DISORDERS | DOV PHARMACEUTICAL, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | disclosed |
| US-7094799-B2 | A single, thermodynamical stable crystal structure, is crystallized from a cooled and agitated solvent solution, analgesic drug for reducing pain | DOV PHARMACEUTICAL, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060100263-A1 | Antipyretic compositions and methods | DOV PHARMACEUTICAL, INC. | 2006-05-11 | — | — | US | disclosed |
| US-20040102638-A1 | Polymorphs of bicifadine hydrochloride | EUTHYMICS BIOSCIENCE, INC. | 2004-05-27 | — | — | US | disclosed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
| US-4231935-A | ANXIOLYTICS AND ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4196120-A | 1,2-BIS(HYDROCARBYLSULFONYLOXY OR HALO METHYL)CYCLOPROPYLBENZENE, OPTICAL ACITIVITY ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4131611-A | ANXIOLYTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149599-A1 | Polymorphs of bicifadine hydrochloride | SF3B5, SFPQ, BBC3 | ADAM17 3502/4885HTR2C 456/4885ATM 4558/4885 |
| US-20070082938-A1 | Polymorphs of bicifadine hydrochloride | SF3B5, SFPQ, BBC3 | ADAM17 3502/4885HTR2C 456/4885ATM 4558/4885 |
| US-20040102638-A1 | Polymorphs of bicifadine hydrochloride | SF3B5, SFPQ, BBC3 | ADAM17 3502/4885HTR2C 456/4885ATM 4558/4885 |
| US-20080009538-A1 | Methods and compositions for the treatment of urinary incontinence | BPHL, MYOF, NISCH | ADAM17 621/4885HTR2C 2154/4885ATM 4109/4885 |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | ACHE, LTC4S, CCR5 | ADAM17 3246/4885HTR2C 704/4885ATM 3639/4885 |
| US-20060100263-A1 | Antipyretic compositions and methods | GABRE, HTR5A, TPH2 | ADAM17 1887/4885HTR2C 16/4885ATM 2216/4885 |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | HTR1B, SLC6A3, CYP1B1 | ADAM17 4336/4885HTR2C 26/4885ATM 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.